Charles Schwab Corporation Common Stock (SCHW) Stock Price Today
Key Stats
- $177.27BMARKET_CAP
- -VOLUME
- FinancialsSECTOR
- $107.21FIFTY_TWO_WEEK_HIGH
- $85.35FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- -ENTERPRISE_VALUE
- 1.26%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Charles Schwab Corporation Common Stock (SCHW) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Charles Schwab Corporation Common Stock has traded between a low of $85.35 and a high of $107.21, highlighting its annual price range. Buy and sell Charles Schwab Corporation Common Stock shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Most Recent News
Wedbush celebrates 18 years with Cboe, highlighting market innovation and expanding digital asset trading.
Wedbush rang the closing bell at Cboe Global Markets to mark 18 years as a Cboe member, celebrating a partnership focused on innovation and market integrity. Since joining in 2008, Wedbush has supported the evolution of financial markets through new ...

Lawsuit challenges government-led censorship of Covid vaccine injury discussions on social media.
The New Civil Liberties Alliance (NCLA) filed an appeal to revive a lawsuit against the Biden Administration and private companies for censoring social media posts by individuals injured by Covid vaccines. Plaintiffs, including vaccine-injured indivi...

Investigation launched into Alignment Healthcare over alleged financial manipulation claims.
Hagens Berman has started investigating Alignment Healthcare after a whistleblower lawsuit accused the company of misclassifying expenses to inflate financial results for 2024 and 2025. The allegations claim this manipulation boosted key metrics, aff...
